Erytech Pharma shares dropped in pre-market trading Monday morning after the company said its eryaspase drug didn’t show statistically significant improvement compared with chemotherapy alone in overall survival for patients with pancreatic cancer.
In the trial, average survival for patients given eryaspase was 7.5 months at the median, compared with 6.7 months for patients who got chemotherapy alone. That difference was not statistically significant, Erytech said.
After the trial Erytech will focus on its program to treat acute lymphoblastic leukemia, the company said.
Erytech Chief Executive Gil Beyen called the results “highly disappointing.”
The stock, which closed last week at $5.48, declined by 33% before the market opened Monday morning.
Leave a Reply